These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25837290)

  • 1. Harm Reduction Agencies as a Potential Site for Buprenorphine Treatment.
    Fox AD; Chamberlain A; Frost T; Cunningham CO
    Subst Abus; 2015; 36(2):155-60. PubMed ID: 25837290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants.
    Fox AD; Chamberlain A; Sohler NL; Frost T; Cunningham CO
    J Subst Abuse Treat; 2015 Jan; 48(1):112-6. PubMed ID: 25205666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
    DeFlavio JR; Rolin SA; Nordstrom BR; Kazal LA
    Rural Remote Health; 2015; 15():3019. PubMed ID: 25651434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and evaluation of a community-based buprenorphine treatment intervention.
    Fox AD; Sohler NL; Frost T; Lopez C; Cunningham CO
    Harm Reduct J; 2017 May; 14(1):23. PubMed ID: 28499432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder.
    Fox AD; Maradiaga J; Weiss L; Sanchez J; Starrels JL; Cunningham CO
    Addict Sci Clin Pract; 2015 Jan; 10(1):2. PubMed ID: 25592182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine maintenance treatment retention improves nationally recommended preventive primary care screenings when integrated into urban federally qualified health centers.
    Haddad MS; Zelenev A; Altice FL
    J Urban Health; 2015 Feb; 92(1):193-213. PubMed ID: 25550126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
    Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients.
    Riggins DP; Cunningham CO; Ning Y; Fox AD
    Subst Abus; 2017; 38(3):297-302. PubMed ID: 27715904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating Buprenorphine Into an Opioid Treatment Program: Tailoring Care for Patients With Opioid Use Disorders.
    Polydorou S; Ross S; Coleman P; Duncan L; Roxas N; Thomas A; Mendoza S; Hansen H
    Psychiatr Serv; 2017 Mar; 68(3):295-298. PubMed ID: 27745534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medication-assisted therapy for opioid-dependent incarcerated populations in New Mexico: statewide efforts to increase access.
    Trigg BG; Dickman SL
    Subst Abus; 2012; 33(1):76-84. PubMed ID: 22263716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient Perspectives Associated with Intended Duration of Buprenorphine Maintenance Therapy.
    Bentzley BS; Barth KS; Back SE; Aronson G; Book SW
    J Subst Abuse Treat; 2015 Sep; 56():48-53. PubMed ID: 25899872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications.
    Bruce RD; Dvoryak S; Sylla L; Altice FL
    Int J Drug Policy; 2007 Aug; 18(4):326-8. PubMed ID: 17689382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Harm Reduction Approach to Treating Opioid Use Disorder in an Independent Primary Care Practice: a Qualitative Study.
    Kapadia SN; Griffin JL; Waldman J; Ziebarth NR; Schackman BR; Behrends CN
    J Gen Intern Med; 2021 Jul; 36(7):1898-1905. PubMed ID: 33469774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting injectable depot buprenorphine from a harm reduction perspective in patients with ongoing substance use and multiple psychiatric comorbidities: a qualitative interview study.
    Johnson B; Monwell B; Capusan AJ
    Harm Reduct J; 2024 Mar; 21(1):68. PubMed ID: 38528531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
    Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
    Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consumer attitudes about opioid addiction treatment: a focus group study in New York City.
    Sohler NL; Weiss L; Egan JE; López CM; Favaro J; Cordero R; Cunningham CO
    J Opioid Manag; 2013; 9(2):111-9. PubMed ID: 23709320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Awareness of, experience with, and attitudes toward buprenorphine among opioid users visiting a New York City syringe exchange program.
    Shah PA; Sohler NL; López C; Fox AD; Cunningham CO
    J Opioid Manag; 2013; 9(6):407-13. PubMed ID: 24481929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Descriptive study: the novel "full spectrum people-with-opioid-use-disorder care model".
    Gadomski R; Bhatt S; Gross J; Dixon JA; Fiuty P; Shapiro M; Fernandez-Mancha R; Salvador J
    Harm Reduct J; 2023 Apr; 20(1):47. PubMed ID: 37046265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medication-assisted treatment with buprenorphine: assessing the evidence.
    Thomas CP; Fullerton CA; Kim M; Montejano L; Lyman DR; Dougherty RH; Daniels AS; Ghose SS; Delphin-Rittmon ME
    Psychiatr Serv; 2014 Feb; 65(2):158-70. PubMed ID: 24247147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.
    Connock M; Juarez-Garcia A; Jowett S; Frew E; Liu Z; Taylor RJ; Fry-Smith A; Day E; Lintzeris N; Roberts T; Burls A; Taylor RS
    Health Technol Assess; 2007 Mar; 11(9):1-171, iii-iv. PubMed ID: 17313907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.